EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent Activity of the Company’s Novel COBRATM Platform, a Conditionally Active T-cell Engaging Therapeutic Designed to Target Solid Tumors – BRISBANE, Calif.–(BUSINESS WIRE)– Maverick Therapeutics Inc., a private biopharmaceutical company pioneering next-generation redirected T-cell targeted immunotherapies, …
Plus »Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
Friday, March 29th 2019 at 7:44pm UTC AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose (RP2D) of 220 …
Plus »Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
Friday, March 29th 2019 at 7:15pm UTC First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia and Multiple Myeloma WARREN, N.J.–(BUSINESS WIRE)– Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from …
Plus »Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
Friday, March 29th 2019 at 7:01pm UTC TORONTO–(BUSINESS WIRE)– Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia. Session Title: …
Plus »Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
Friday, March 29th 2019 at 7:00pm UTC Data to be Presented at AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of …
Plus »Definiens et Ultivue annoncent une collaboration visant à développer des offres conjointes dans le domaine de l’immunofluorescence multiplexe et de l’analyse d’image numérique par intelligence artificielle
Friday, March 29th 2019 at 6:03pm UTC CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Ultivue, un développeur de tests d’identification et de quantification des biomarqueurs tissulaires destinés aux laboratoires de recherche translationnelle et en pathologie, et Definiens, une société pionnière de l’analyse des images basée sur l’intelligence artificielle, ont annoncé aujourd’hui une collaboration visant …
Plus »Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis
Friday, March 29th 2019 at 3:11pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI) based image analysis, today announced a collaboration to expand Definiens standardized IO-Panel capabilities to IF. The …
Plus »CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
Friday, March 29th 2019 at 1:00pm UTC VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the …
Plus »Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
Friday, March 29th 2019 at 12:12pm UTC The CHMP adopted two positive opinions recommending European Commission approval of: REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant IMNOVID in combination with bortezomib and dexamethasone (PVd), for adult …
Plus »Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Friday, March 29th 2019 at 12:00pm UTC -Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN) today announced completion of enrollment in the potentially pivotal innovaTV 204 phase 2 clinical trial evaluating the efficacy, safety and tolerability of …
Plus »
